This feature highlights changes in clinical trial organizations’ personnel.

Acadia Pharmaceuticals

Mary-Lacey Reuther has been hired by Acadia Pharmaceuticals to fill the role of vice president of government affairs and policy. Most recently, Reuther was senior director of federal affairs at Astellas Pharma.

Alnylam Pharmaceuticals

Yvonne Greenstreet, chief operating officer at Alnylam Pharmaceuticals, will assume the dual roles of president and chief operating officer at the company starting Oct. 1.

AnaptysBio

Paul Lizzul has been named chief medical officer of AnaptysBio. Prior to this position, Lizzul was global development lead for inflammation at Amgen.

ANI Pharmaceuticals

Nikhil Lalwani has been appointed president and CEO of ANI Pharmaceuticals. Lalwani was previously the CEO of Cipla USA.

Arcutis Biotherapeutics

Bethany Dudek has been named vice president of quality at Arcutis Biotherapeutics. Dudek recently served as executive director of quality Europe at Kite Pharma.

Aslan Pharmaceuticals

Kenneth Kobayashi, former senior medical director of Dermira, has been appointed chief medical officer of Aslan Pharmaceuticals.

Aspen Neuroscience

Jeanne Loring, co-founder and chief scientific officer of Aspen Neuroscience, has assumed the role of special adviser to the company’s research and development committee.

CN Bio

James Craven has been named chief commercial officer at CN Bio. Prior to this new appointment, Craven was director of market strategy and commercial delivery at Brooks Life Sciences. Additionally, CN Bio has named Brian Manning, former senior director of business development at InSphero, as the company’s U.S. head of sales.

CureVac

Franz-Werner Haas, chief corporate officer of CureVac, has assumed his new role of CEO at the company. CureVac has also named Igor Splawski, former executive director and site head at Novartis, as its chief scientific officer.

Dicerna Pharmaceuticals

Shreeram Aradhye has been appointed executive vice president and chief medical officer at Dicerna Pharmaceuticals. Previously, Aradhye was executive vice president and chief development officer at Axcella Health.

Disc Medicine

Jonathan Yu has been named senior vice president of corporate strategy at Disc Medicine. Previously, Yu was co-founder and vice president of corporate strategy, finance and operations at Qpex Biopharma. Disc also named William Savage as vice president of clinical development. Savage most recently served as senior medical director at Magenta Therapeutics.

Excision BioTherapeutics

Excision BioTherapeutics has appointed TJ Cradick, former head of genome editing at CRISPR Therapeutics, to the role of chief scientific officer.

Integrity Laboratories

Integrity Laboratories has appointed Maria Cekanova its chief scientific officer. Previously, Cekanova was director of the translational research laboratory and research associate professor of oncology at the University of Tennessee.

Legend Biotech

Board members at Legend Biotech have named Frank Zhang CEO of the company. Zhang will step down from his current position of CEO at GenScript.

Melinta Therapeutics

Christine Ann Miller, who most recently served as a leader in the global and U.S. product portfolio for Novartis subsidiary Sandoz, has been named president and CEO of Melinta Therapeutics.

MiMedx Group

MiMedx Group has appointed Rohit Kashyap to the positions of executive vice president and chief commercial officer. Kashyap was most recently president of global commercial at Acelity.

Mission Therapeutics

Mission Therapeutics has promoted Paul Thompson, the company’s vice president of clinical development, to the role of chief scientific officer. Mission also promoted Nick Edmunds from his role as vice president and head of DUB Discovery to the role of chief technology officer.

NBE-Therapeutics

Bertrand Damous will step down from his position of CEO at GeneProt to join NBE-Therapeutics as its new CEO.

NeoPhore

NeoPhore has appointed Martin Drysdale to the role of vice president of drug discovery. Drysdale was most recently the head of the drug discovery unit at the Cancer Research UK Beatson Institute.

Nura Bio

Nura Bio has tapped Alpna Seth, former chief operating officer of Biogen, as its newest CEO.

Oxurion

Grace Chang, former chief medical officer at Notal Vision, has been named chief medical officer at Oxurion.

Parexel

Jorge Camarero has been appointed to a vice president position at Parexel. Camarero was previously a Committee for Medicinal Products for Human Use alternate member at the European Medicines Agency.

PharmOptima

Anthony Rohr will now lead PharmOptima, a member of Genesis Drug Discovery & Development, as its newest CEO. Formerly, Rohr was senior director of lab operations at MPI Research.

Premier Research

Cassandra Matney has been named senior medical director of Premier Research. Matney was previously a senior manager of medical affairs liaison at Astellas Pharma.

Regulus Therapeutics

Denis Drygin has been appointed chief scientific officer at Regulus Therapeutics. Drygin was most recently vice president of research and development at Pimera.

Selecta Biosciences

Selecta Biosciences has appointed Peter Traber to the role of chief medical officer. Traber has been serving as interim chief medical officer for the company prior to this full-time appointment.

Swedish Biomimetics

Zsolt Lavotha, former CEO of Orexo, has been appointed acting CEO of Swedish Biomimetics.

Synlogic

Antoine Awad, head of technical operations of Synlogic, has been promoted to the role of chief operating officer.

Valo Therapeutics

Valo Therapeutics has found its newest CEO in Paul Higham, an industry veteran who formerly served as CEO at Glycotope and Immatics Biotechnologies.

Viroclinics Biosciences

Davide Molho has been appointed CEO of Viroclinics Biosciences. Molho most recently served as CEO of Evolution Research Group.